Acceptability of long-acting injectables for TB preventative treatment among high-risk groups
The International Journal of Tuberculosis and Lung Disease · 29.06.2026 · 30 (7) · 328-330
DOI: 10.5588/ijtld.25.0740 ↗Kurz gefasst
Fachartikel in der Zeitschrift The International Journal of Tuberculosis and Lung Disease, erschienen am 29.06.2026. Verfasst von R L Demissie und 8 weiteren Autor:innen. Beteiligte Einrichtung: Emory University, Rollins School of Public Health, Atlanta, GA, USA.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Emory University, Rollins School of Public Health, Atlanta, GA, USA.
- National Center for Tuberculosis and Lung Diseases, Tbilisi, GA, USA;, David Tvildiani Medical University Tbilisi, Tbilisi, GA, USA;, The University of Georgia, Tbilisi, GA, USA.
- National Center for Tuberculosis and Lung Diseases, Tbilisi, GA, USA.
- National Center for Tuberculosis and Lung Diseases, Tbilisi, GA, USA;, European University, Tbilisi, GA, USA.
- Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Zitieren
APA
Demissie, R. L., Kipiani, M., Goginashvili, L., Papuashvili, P., Avaliani, Z., Collins, L. F., Ontiveros, V. C., Magee, M. J., & Kempker, R. R. (2026). Acceptability of long-acting injectables for TB preventative treatment among high-risk groups. The International Journal of Tuberculosis and Lung Disease, 30(7), 328-330. https://doi.org/10.5588/ijtld.25.0740
Vancouver
Demissie RL, Kipiani M, Goginashvili L, Papuashvili P, Avaliani Z, Collins LF, et al. Acceptability of long-acting injectables for TB preventative treatment among high-risk groups. The International Journal of Tuberculosis and Lung Disease. 2026;30(7):328-330. doi:10.5588/ijtld.25.0740
BibTeX
@article{Demissie2026,
author = {Demissie, R L and Kipiani, M and Goginashvili, L and Papuashvili, P and Avaliani, Z and Collins, L F and Ontiveros, V C and Magee, M J and Kempker, R R},
title = {Acceptability of long-acting injectables for TB preventative treatment among high-risk groups},
journal = {The International Journal of Tuberculosis and Lung Disease},
year = {2026},
volume = {30},
number = {7},
pages = {328--330},
doi = {10.5588/ijtld.25.0740}
}
EUVIMED